EU/3/04/201

Table of contents

About

On 8 June 2004, orphan designation (EU/3/04/201) was granted by the European Commission to Ark Therapeutics Limited, United Kingdom, for vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar for the prevention of stenosis in synthetic grafts used in haemodialysis.

In February 2014, Ark Therapeutics Limited changed name to Finvector Vision Therapies Limited.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

Key facts

Active substance
Vascular endothelial growth factor-D gene in an adenoviral vector for use with a collagen collar
Disease / condition
Prevention of stenosis in synthetic grafts used in haemodialysis
Date of decision
08/06/2004
Outcome
Positive
Orphan decision number
EU/3/04/201

Sponsor's contact details

Finvector Vision Therapies Limited
Sanderum House
Oakley Road Chinnor
Oxfordshire OX39 4TW
United Kingdom
Tel. +44 1844 3556244
Fax +44 1844 353553

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating